Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Moderate weight gain is usual after starting insulin therapy. The identification and quantification of factors associated with weight gain may help target strategies for avoidance of weight gain. RESEARCH DESIGN AND METHODS: The noninterventional CREDIT (Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy) study included data from people with type 2 diabetes starting any insulin in 314 centers, in 12 countries. From a number of predefined candidate explanatory variables, analyses identified factors associated with weight gain 1 year after starting insulin treatment, after adjusting for investigational site as a random factor. A multivariable backward regression analysis selected a subset of these factors associated with weight gain. RESULTS: We studied the 2,179 people with data for body weight change at 1 year and for potential predictive factors. The mean weight gain was 1.78 kg, and 24% gained ≥5.0 kg. Baseline factors associated with weight gain were BMI, A1C, insulin regimen, insulin dose, other glucose-lowering therapies, and hypertension; at 1 year, additional factors were A1C, insulin regimen, insulin dose, and use of other glucose-lowering therapies. In multivariable analysis, weight gain at 1 year was associated with a higher A1C at baseline, a higher insulin dose at baseline and at 1 year, and a lower baseline BMI. CONCLUSIONS: By the time insulin was started, a high baseline A1C and insulin dose requirements were independently associated with greater weight gain, as was lower baseline BMI. Insulin regimen per se was not a predictive factor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“U500 regular insulin (contains 500 units/mL of regular insulin) may improve glycemia in the therapy of persons with DM who have severe insulin resistance (eg, require >200 total units of insulin/day).1102–1105”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1102]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Research works printed but not linked: 1
- Home, 2013, Impact of insulin detemir on weight change in relation to baseline BMI: observations from the A1chieve Study, Diabetes, 62, A246
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
“The noninterventional Cardiovascular Risk Evaluation in People With Type 2 Diabetes on Insulin Therapy (CREDIT) study (115) of insulin started”
BackgroundSelf-citationObermayer, A. M., Tripolt, N. J., Pferschy, P. N., Kojzar, H., Aziz, F., Müller, A., Schauer, M., Oulhaj, A., Aberer, F., Sourij, C., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1622 · Cited by 135
“with insulin-treated type 2 diabetes often struggle with weight gain (6), resulting in a”
BackgroundInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
“A targeted use of diabetes pharmacotherapy can be an effective strategy in helping to manage IAWG.”
BackgroundInfluentialCichosz, S. L., Johansen, M. D., & Hejlesen, O. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815611680 · Cited by 101
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 92
“The weight gain in these studies was similar to that observed in the earliest studies with IGlar (4) as well as in a large observational study (121), and occurred in the setting of superior HbA 1c reduction and with similar, or in ONWARDS 5, higher, total insulin dose of icodec vs once-daily…”
Jakubowicz, D., Landau, Z., Tsameret, S., Wainstein, J., Raz, I., Ahren, B., Chapnik, N., Barnea, M., Ganz, T., Menaged, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1142 · Cited by 77
“In addition, as exogenous insulin predisposes to weight gain (8) and is associated with increased risk of cardiovascular events andall-causemortality in adose-dependent fashion (2), the improvement of glycemic control with significant reduction of TDID in the 3Mdiet is of utmost”
BackgroundInagaki, N., Harashima, S.-I., Maruyama, N., Kawaguchi, Y., Goda, M., & Iijima, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0407-4 · Cited by 70
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Mansour, A. A., Alibrahim, N. T. Y., Alidrisi, H. A., Alhamza, A. H. A., Almomin, A., Zaboon, I. A., Kadhim, M. B., Hussein, R. N., Nwayyir, H. A., Mohammed, A. G., et al. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.008 · Cited by 64
Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 54
“Reduction in Body Weight Insulin therapy often results in an increase in body weight (22, 23).”
BackgroundInsulin therapy, weight gain and prognosis
Hodish, I. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13367 · Cited by 48
“78 kg and 24% of participants gained ≥5 kg.(9) Noteworthy were participants' baseline characteristics.”
BackgroundMontvida, O., Klein, K., Kumar, S., Khunti, K., & Paul, S. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12790 · Cited by 43
Jansen, H. J., Vervoort, G. M. M., de Haan, A. F. J., Netten, P. M., de Grauw, W. J., & Tack, C. J. (2014) · Diabetes Care · doi:10.2337/dc13-1205 · Cited by 40
“(24) found in a large cohort of patients with T2DM starting on any type of insulin that starting insulin dose was associated with a greater weight gain, which is in agreement with our data.”
ResultImprovement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Goto, Y., Otsuka, Y., Ashida, K., Nagayama, A., Hasuzawa, N., Iwata, S., Hara, K., Tsuruta, M., Wada, N., Motomura, S., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0082 · Cited by 39
Paul, S. K., Shaw, J. E., Montvida, O., & Klein, K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12761 · Cited by 39
Watada, H., Kaneko, S., Komatsu, M., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Nakamura, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13859 · Cited by 37
“The initial weight loss observed in both treatment groups may be the result of the decrease in insulin dose from pre-trial doses of approximately 28 U to starting doses of 10 dose steps/U, or up to 16 dose steps/U in some cases.(22) The additional weight loss seen in the IDegLira group is attributed to the weight-lowe…”
Anyanwagu, U., Mamza, J., Gordon, J. P., Donnelly, R., & IDRIS, I. R. (2017) · Diabetic Medicine · doi:10.1111/dme.13518 · Cited by 34
“This observation was supported by findings from two other studies [29, 30].”
BackgroundResultUmpierrez, G. E., SKOLNIK, N., DEX, T. A., Traylor, L., Chao, J., & Shaefer, C. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13653 · Cited by 36
Sone, H., Kaneko, T., Shiki, K., Tachibana, Y., Pfarr, E., Lee, J., & Tajima, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13909 · Cited by 35
“Body weight gain is a typical issue associated with insulin.(6-8) The results of this study suggest that adding empagliflozin to insulin treatment mitigates this issue, as body weight and waist circumference were both significantly decreased with empagliflozin 10 mg or 25 mg after 16 weeks of treatment and these impro…”
BackgroundFreemantle, N., Danchin, N., Calvi-Gries, F., Vincent, M., & Home, P. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12598 · Cited by 30
Self-citationGomez-Peralta, F., & Abreu, C. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 27
“Aggravating the above mentioned challenges, the classic treatments for T2DM (sulfonylurea [SU] and insulin) are associated with clinically relevant weight increases.(5) Possibly, the second most significant barrier to achieve glycemic control objective in T2DM is the risk of hypoglycemia.”
BackgroundWysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Home, P., Dain, M., Freemantle, N., Kawamori, R., Pfohl, M., Brette, S., Pilorget, V., Scherbaum, W. A., Vespasiani, G., Vincent, M., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.030 · Cited by 28
“[29] Balkau B, Home PD, Vincent M, Marre M, Freemantle N.”
BackgroundSelf-citationSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
John, M., Gopinath, D., & Jagesh, R. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172268 · Cited by 25
“Higher insulin dose along with higher baseline HbA1c and lower body mass index at baseline were factors associated with higher weight gain in subjects on insulin.[34,35] Agents such as thiazolidinedione and SU used in association with insulin leads to weight gain.”
BackgroundTreatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 30
Gagnon, É., Mitchell, P. L., & Arsenault, B. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac758 · Cited by 23
Simplification of complex insulin therapy: a story of dogma and therapeutic resignation
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108958 · Cited by 22
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0587-6 · Cited by 19
“We were also unable to obtain longitudinal data on insulin doses, which are important in assessing insulininduced weight gain [33], which in turn could potentially influence glycaemic and CV outcomes.”
BackgroundInagaki, N., Harashima, S., Kaku, K., Kondo, K., Maruyama, N., Otsuka, M., Kawaguchi, Y., & Iijima, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13152 · Cited by 15
Anderten, H., Dippel, F. W., & Kostev, K. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814566232 · Cited by 15
Prediction of excessive weight gain in insulin treated patients with type 2 diabetes
Cichosz, S. L., Lundby‐Christensen, L., Johansen, M. D., Tarnow, L., Almdal, T., Hejlesen, O. K., & The C.I.M.T. Trial Group (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12418 · Cited by 14
“Balkau et al.22 investigated factors associated with weight gain in people with T2DM starting insulin treatment and found that the main factors associated with weight gain were higher insulin dose, higher baseline HbA1c, and lower baseline body mass index (BMI).”
BackgroundInfluentialRibeiro, S. A. G., Pedrotti, M., Hespanhol, L. C., Balieiro, C. C. A., Paqualotto, E., Silva, R. R. E., Gauza, M. D. M., & de Sá, J. R. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100285 · Cited by 12
“However, one of the barriers to achieving this control is patients ’ reluctance to initiate and adhere to a therapeutic regimen involving insulin administration once or twice daily [19,39].”
Bramlage, P., Bluhmki, T., Fleischmann, H., Kaltheuner, M., Beyersmann, J., Holl, R. W., & Danne, T. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000301 · Cited by 11
“5 kg higher weight gain at 1 year.(22) One potential explanation for this disparity centers around disease severity.”
BackgroundResultInfluentialYadgar‐Yalda, R., Colman, P. G., Fourlanos, S., & Wentworth, J. M. (2016) · Internal Medicine Journal · doi:10.1111/imj.13122 · Cited by 10
Insulin for people with type 2 diabetes mellitus
Vanderpant, N., Ward, E., Farrell, E., & Theodoraki, A. (2024) · BMJ · doi:10.1136/bmj-2023-078015 · Cited by 9
Wade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M. A., Qureshi, K., Syn, W., & Fleetwood, V. A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70344 · Cited by 9
Edens, M. A., van Dijk, P. R., Hak, E., & Bilo, H. J. G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110719 · Cited by 8
Bramlage, P., Bluhmki, T., Rathmann, W., Kaltheuner, M., Beyersmann, J., & Danne, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.015 · Cited by 8
Popoviciu, M. S., Păduraru, L., Rahman, M., Supti, F. A., Stoica, R. A., Reurean‐Pintilei, D., Bica, C. I., & Cavalu, S. D. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1439 · Cited by 8
“As a result, increased adiponectin expression and decreased leptin expression promote energy expenditure and lipolysis, which reduce body weight [71].”
Zhang, Q., Zhao, X., Chen, M., Fang, Z., Chen, Y., & Wang, Y. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.09.005 · Cited by 8
“[8] found that a high baseline A1 C and insulin dose requirements were independently associated with greater weight gain in people with type 2 diabetes starting on insulin.”
BackgroundBlonde, L., Marre, M., Vincent, M., Brette, S., Pilorget, V., Danchin, N., Vespasiani, G., & Home, P. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.016 · Cited by 7
“[10] Balkau B, Home PD, Vincent M, Marre M, Freemantle N.”
BackgroundSelf-citationAnyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.08.005 · Cited by 7
“[27,28].”
Buysman, E. K., Fan, T., Blauer-Peterson, C. J., & Miller‐Wilson, L. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.19 · Cited by 7
Edens, M. A., van Dijk, P. R., Hak, E., & Bilo, H. J. G. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.212 · Cited by 7
Guo, L., Luo, W., Tan, T., Gong, F., Liu, X., Rao, S.-Q., Lian, F., Liu, J., Chen, X., Li, G., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.05.013 · Cited by 5
Factors involved in body weight loss and its maintenance in morbidly obese inpatients
Tadokoro, R., Iida, T., Mikura, K., Imai, H., Murai, N., Kaji, M., Hashizume, M., Kigawa, Y., Endo, K., Iizaka, T., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00403-y · Cited by 5
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 7
Gordon, J. P., Evans, M., Puelles, J., & McEwan, P. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0134-y · Cited by 4
“These studies illustrate that the identification of phenotypic characteristics that are predictive of weight gain at the time of treatment initiation or escalation may help to develop strategies for avoidance of weight gain [5], and any downstream adverse patient outcomes and excess resource utilization associated wit…”
BackgroundResultHome, P. D., Calvi-Gries, F., Blonde, L., Pilorget, V., Berlingieri, J., & Freemantle, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13179 · Cited by 4
“84 for each step.(14) No variables required transformation, except at year 4 when baseline DBP and current HbA1c and change from baseline HbA1c fitted best to restricted cubic splines.”
BackgroundSelf-citationFor debate; pharmacological priorities in advanced type 2 diabetes
Hodish, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107510 · Cited by 4
Macronutrient composition and metabolic regulation: Do our islets care what we eat?
Pesta, D. H., & Jordan, J. (2022) · Acta Physiologica · doi:10.1111/apha.13895 · Cited by 4
Prinz, N., Schwandt, A., Borgert, B., Hartmann, B., Kempe, H., Mader, J. K., Merger, S. R., Weber-Lauffer, R., Wosch, F. J., Holl, R. W., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0144 · Cited by 3
“15 Altogether, our data and those of previous observational studies 13,14 provide reassurance to caregivers and patients to timely start insulin even if the patient is obese and having weight concerns to prevent long-term diabetes-related complications.”
Finer, N. (2014) · Diabetes Care · doi:10.2337/dc14-1916 · Cited by 3
“(1) finds that people who are thinner and have more poorly controlled diabetes gain the most weight when started on insulin.”
BackgroundThe Double Whammy of Obesity and Diabetes on Female Reproductive Health
Thong, E. P., & Burden, C. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1723777 · Cited by 2
Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation
Deng, B., Kireev, V. A., Melentyeva, K. V., Kovalenko, I., & Pakhomov, O. V. (2020) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo30.01.034 · Cited by 2
Renda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
“Another study revealed that the increase in body weight associated with insulin therapy was highly dependent on baseline A1C and insulin dose [48].”
BackgroundBedeutung der Insulintherapie bei Menschen mit Diabetes mellitus Typ 2
Jecht, M., Dötsch, I., & Häussler, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01236-3 · Cited by 1
Stolarczyk, S. P., Romańczuk, K. B., Wójcik, Z. M., Omasta, B., Rybak, D., Czerska, M. A., Pietrukaniec, P. D., Krupa, O., Kamińska-Omasta, K., & Furtak, K. (2025) · Quality in Sport · doi:10.12775/qs.2025.38.58230 · Cited by 1
Candido, R., Buzzetti, R., Consoli, A., Irace, C., Torre, E., Trevisan, R., Fadini, G. P., T2D once-Weekly Insulin Expert Panel Group, Berra, C., Bartolo, P. D., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02619-8 · Cited by 1
“100% 17.”
Levy, N., NERLINO, K., BONGALOS, S., Dasilva, A., UZOR, C., Liang, Y. J., & SONUBI, O. (2026) · JMIR Formative Research · doi:10.2196/76993 · Cited by 1
“Insulin lowers blood sugar but introduces the risk of hypoglycemia and weight gain [1-5].”
Ishikawa, M., Takai, M., Maeda, H., Kanamori, A., Kubota, A., Amemiya, H., Iizuka, T., Iemitsu, K., Iwasaki, T., Uehara, G., et al. (2018) · Journal of Endocrinology and Metabolism · doi:10.14740/jem540 · Cited by 1
Ling, W., Wang, Y.-C., Huang, Y., Ou, Y.-X., & Jiang, Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.94976 · Cited by 1
Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
Halimi, S., Charbonnel, B. H., Monguillon, P., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30011-0 · Cited by 1
Balkau, B., Home, P., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc14-2152
“We very much concur with Nick Finer that weight is not everything (1).”
Self-citationTreatment: Concepts and new developments
Bloomgarden, Z. T., & Drexler, A. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12381
“Weight gain is particularly seen with higher baseline HbA1c levels and at higher insulin doses, and basal-bolus and premixed regimens track with a greater likelihood of >5 kg weight gain.(8) Approaches to minimize weight gain include insulin administration with metformin(9,10) and with glucagon-like peptide-1 receptor…”
BackgroundNúñez‐Sánchez, M. Á., Cervantes-Cuesta, M. Á., Brocal-Ibañez, P., Salmerón-Arjona, E., León-Martínez, L. P., & Cerezo-Sanmartin, M. (2016) · Revista de Calidad Asistencial · doi:10.1016/j.cali.2016.09.005
Gewichtszunahme bei insulinbehandelten Diabetespatienten
Jecht, M. (2017) · Der Diabetologe · doi:10.1007/s11428-016-0179-1
Sánchez, J. M. L. (2017) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2017.04.00107
Chapitre 15 – Diabète de type 2 : forte insulinorésistance
Monnier, L., RABASA-LHORET, R. P. R., & Colette, C. (2017)
Montvida, O. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122920
Farinha da casca de maracujá (Passiflora edulis): efeitos no tratamento e na prevenção da obesidade
Lima, G. C. (2015) · doi:10.47749/t/unicamp.2015.962141 · Cited by 2
Chapter 1. Uncontrolled Type 2 Diabetes
(2015) · The American Pharmacists Association eBooks · doi:10.21019/9781582122397.ch1
Ike, A., Shirai, K., & Saku, K. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.07.004
Ling, W., Yi, H., Xiao, Y., Yan-Mei, H., Yang-Fu, O., Hong, X., & Hai‐Lu, Z. (2020) · doi:10.21203/rs.3.rs-16319/v1
“[28] Balkau B, Home PD, Vincent M, Marre M, Freemantle N.”
BackgroundSingh, G., Krauthamer, M., & Bjalme-Evans, M. (2021) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20210604.17
Islam, T., Das, A. K., Rahaman, M. A., Nahar, S., Jahan, Q. A., Ansari, M. J., Prasad, I., Saifuddin, M., Islam, M., & Sharifuzzaman, M. (2022) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_7_22
Metadata
- Authors
- Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N.
- Affiliations
- Inserm (FR)
- Newcastle University (GB)
- Sanofi (France) (FR)
- University College London (GB)
- Corresponding author
- Balkau, Beverley
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2108-2113
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128294807
- Cited by
- 77
- References
- 26
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 9 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 12 · 2014: 3
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, weight gain, insulin dose, HbA1c, body mass index, insulin regimens, glucose-lowering therapy, hypertension, risk factors
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Longitudinal Studies, Male, Middle Aged, Risk Factors, Weight Gain, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.